205results about "Hormone peptides" patented technology

The invention discloses an SmCLE mature peptide and application thereof in plant stress resistance, and belongs to the technical field of plant biology. According to the technical scheme, the SmCLE mature peptide is provided, and the amino acid sequence of the SmCLE mature peptide is SEQ ID NO: 1. The CLE peptide is applied to the aspect of plant stress resistance, the problem that an existing CLE peptide cannot be applied to stress resistance of plants, especially medicinal plants or non-mode crops is solved, the CLE peptide has high biocompatibility and targeting performance, and the biomass and yield of the crops in a stress environment can be remarkably improved.

The present invention provides an antibody pair that binds human mature prolactin, comprising: a monoclonal antibody 1 or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin, and a monoclonal antibody 2 or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin. The present invention also provides use of the antibody pair of the present invention in manufacturing a kit for measuring prolactin in a biological sample. The present invention also provides a monoclonal antibody or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin and a monoclonal antibody or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin, respectively. The present invention also provides a method for measuring prolactin in a biological sample using the antibody pair of the present invention. The present invention also provides a method for producing a monoclonal antibody in the antibody pair of the present invention.

The invention relates to PYY analogues having alanine at position 4, lysine at position 7, QRY as the C-terminal end and a half-life extending group. The analogues of the invention are soluble around pH 6 and 7. The invention also relates to pharmaceutical compositions comprising such PYY analogues, and to the medical use of the analogues.

The invention relates to the field of biological medicine preparation, in particular to a semi-synthesis preparation method of canagliflozin, which comprises the following steps: (1) under the condition that the pH value is 9.0-11.5, carrying out selective protection on lysine epsilon amino of a canagliflozin intermediate 36AA to obtain Boc-protected 36 peptide (BoC-36AA); (2) under the condition that the pH (Potential of Hydrogen) is 8.5 to 9.0, carrying out a reaction on side chain Glu-eicosandioic acid and the lysine alpha-amino group of the Boc-36AA to obtain 36-AA (SC-36AA) with a side chain; (3) carrying out a reaction on the SC-36AA and prolinamide, so as to obtain a canagliflozin precursor; and (4) cracking the canagliflozin precursor to obtain the canagliflozin. The preparation method is simple to operate, low in cost, high in yield and high in purity, the total reaction yield is more than 56%, and the HPLC (high performance liquid chromatography) purity is more than or equal to 99.6%.

The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their HbA1c goal using GLP-1 RA treatment. The present invention provides a method for improving weight management in a patient in need thereof, comprising administering to said patient tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their weight management goal using GLP-1 RA treatment.

To provide a method for generating oligocortical spheroids (OCS) from pluripotent stem cells (PSC).SOLUTION: A method comprises the steps for: a) generating a neurocortical spheroid (NCS) through neurocortical patterning of pluripotent stem cells; b) subjecting the neurocortical spheroid to timed exposure to defined oligodendrocyte lineage growth factors and / or hormones, to promote proliferation, survival and / or expansion of native oligodendrocyte progenitor cell (OPC) populations within the neurocortical spheroid, thereby generating the oligocortical spheroid, wherein the oligocortical spheroid contains oligodendrocyte progenitor cells capable of differentiating into myelinating oligodendrocytes (ODCs) that are capable of myelinating axons.SELECTED DRAWING: Figure 1-1

The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants thereof and b) a second peptide with agonist activity of OR1 and OR2 receptors or functional fragments or derivatives, or biologically active variants thereof.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

The present invention relates to the fields of molecular biology, virology, immunology and medicine, and in particular to a preparation method for a castrating AP205 virus-like particle subunit vaccine.

Provided herein are heterodimeric proteins (e.g., multispecific antibodies) that exhibit enhanced binding to human Fc gamma receptor IIIA (FcγRIIIA) compared to naturally occurring antibodies and retain good manufacturability. Such heterodimeric proteins are particularly useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for producing these heterodimeric proteins.

Novel kisspeptin-13 or KP-13 peptides and KP-13 satellites or modified peptides (KPSATs) are disclosed having improved therapeutic benefits in regulating pathophysiological changes in various tissues, particularly lung tissue. These KPSATs have improved antiproliferative effects and non-cytotoxic effects on airway smooth muscle cells and tissue.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

To provide pharmaceutical compositions applicable for treatment of diseases caused by the aggregation of human Islet Amyloid Polypeptide (human IAPP) or diseases whose progression is related to the aggregation of human IAPP.SOLUTION: The present invention provides pharmaceutical compositions for inhibiting the aggregation of human IAPP, comprising IAPP peptides comprising a specific amino acid sequence, and one or more pharmaceutically acceptable excipients.SELECTED DRAWING: None

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

The present invention relates to the treatment of infectious diseases. In this study, we identify potential defense mechanisms involved in maintaining brain vascular integrity during bacterial infection and perform RNA analysis of primary endothelial cells isolated from human skin (HDMEC) or brain (HBMEC) microvessels. The cells were either uninfected or infected with Neisseria meningitidis in vitro. We found 40 genes, especially ANGPTL4, that are specifically regulated in brain endothelial cells during infection. In the context of sepsis, ANGPTL4 was found to be the main barrier stabilizing protein with a defensive effect against bacterial infection. ANGPTL4 (or derived peptides) also showed potential as an adjunctive therapy to reduce bacteria-induced vascular dysfunction and mortality. Thus, the present invention relates to peptides derived from the protein ANGPTL4 and their use in the treatment of infectious diseases.

This invention provides a side-chain coupled compound of a cell-binding molecule having a branched linker and an amanita toxin compound. [Solution] A side-chain conjugated compound of formula (I), TIFF2026097851000286.tif25170 In one embodiment, a side-chain conjugated compound is provided, in which T is a cell-binding agent / molecule, W is a C1-C18 extension unit, and D is an amanita toxin, or an isotope of a chemical element, or a pharmaceutically acceptable salt, hydrate, or hydrated salt; or a polymorphic crystal; or an optical isomer, racemate, diastereomer, or enantiomer thereof.

Provided herein are engineered or modified cell lines in which the expression of at least one of ADM2, AURKA, BCL2, CCND1, CHD1, CREB3L3, RIGI / DDX58, ECSIT, EHHADH, ERBB2, FAS, FBXW7, FGFR3, FOXL2, GATA1, HDAC5, HOXA5, HSP90B1, IL6, ITGA2B, KAT5, LAS1L, LIF, NFKB1, NFKB2, NFKB1A, NFE2L2, NGEF, NME1, NR3C1, POLN, PPAR-A, PTEN, RELB, RPA1, RXRA, SMAD4, SS18, TCF7, TGM2, THEM6, TNFAIP3, TP63, TRPC1, DBH, ITGAM, HHEX, TXNIP, ASNS, PLEKH02, CDKN1A, C5orf64, COL20A1, GJB3, ISYNA1, PARD6G-AS1, ACTA1, ACTC1, ADCY10, ADCY4, ADORA2A, ALKBH5, ATP1A4, ATP1B2, ATP2B2, BAIAP3, BAZ1B, BTK, CBL, CCNA1, CD14, CLTC, COPS3, CRHR2, CXADR, DAPK1, DCTN5, DYNLRB1, EME2, EXOC3L1, EYA3, EYA4, FANCA, FEN1, GAK, GCGR, GHSR, GSK3B, H2BC5, H4C7, H4C8, HAP1, HCAR1, INO80, KCNB1, LAT2, LIN7C, MAP1B, MBD4, MYH11, MYH15, MYH3, MYH7B, NAPA, NKD2, NLRP5, NPM2, NR4A3, NFRKB, PAXIP1, PIAS1, PIAS4, POLE, POLE3, POLD1, POLH, PPP4R2, PTGER3, RAB25, RAB40C, RAB44, RAD9A, REV1, RIF1, RNF111, RNF168, RNF4, RPA4, RTEL1, SCRIB, SNRNP70, SPHK1, STX3, SYT1, SYT2, SYT5, SYTL1, SYNJ2, TERF2, TNFSF10, TNPO2, TOP3A, TRIM25, TRIM72, TXLNA, UBA7, UNC5A, VAV3, VPS18, WASL, XRN2, and YY1 is altered as compared to a control cell line. Also provided are methods of producing recombinant AAV particles in said engineered or modified cell lines.

The present invention relates to a photochemical process for the production of C-terminal α-amides, a class of compounds that represent up to half of all biologically relevant peptide hormones. The invention provides a simple, versatile and economically efficient process suitable for large-scale production.

Therapeutic mRNA molecules are provided that are expressible to provide a target polypeptide or protein.SOLUTION: The RNA molecule can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided is a DNA template that can be transcribed to provide a target mRNA and that can have altered nucleotides such as reduced deoxyadenosine. The present invention also provides a process for producing a therapeutic mRNA molecule. An RNA molecule can be translated in vitro or in vivo to provide an active polypeptide or protein.SELECTED DRAWING: Figure 1

The present invention provides, inter alia, apelin receptor agonists having increased half-life, reduced desensitization, improved apelin receptor signaling properties (e.g., bias of G a signaling over arrestin signaling), enhanced stability, and / or enhanced binding to apelin receptors.

One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.

This provides a treatment method for iron metabolism disorders using antibodies. [Solution] Provided are an antibody and its antigen-binding fragment that bind to type II transmembrane serine protease 6 (TMPRSS6) on the cell surface and increase hepcidin expression, as well as a method for treating iron metabolism disorders using the anti-TMPRSS6 antibody and fragment. The anti-TMPRSS6 antibody disclosed herein can be used to treat iron overload, particularly iron metabolism disorders such as β-thalassemia including non-transfusion-dependent thalassemia, and other disorders of ineffective hematopoiesis.

Provided herein are methods of determining sensitivity to dose intense chemotherapy regimens based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index). Further provided are methods of treating cancer patients determined to be sensitive to dose intense chemotherapy therapy by the SETER / PR index. Also provided herein are methods for determining prognosis based on the SET2,3 index.

The present invention provides a method for treating obesity or an obesity-related disease or disorder, comprising administering a PYY analog in combination with an incretin, wherein the patient's insulin sensitivity is improved with treatment.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

The present invention encompasses polypeptides of Formula (I), and pharmaceutically acceptable salts thereof that are effective as amylin analogs. Amylin analogs of Formula (I) find use in the treatment of metabolic disorders or metabolic syndrome in a subject.

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.

This application relates to polypeptide analogs, or derivatives thereof, and methods for their preparation and use, and particularly to polypeptide analogs or derivatives thereof having agonistic activity against the islet amyloid polypeptide receptor. The peptide analogs or derivatives thereof provided in this application have good agonistic activity against the islet amyloid polypeptide receptor, and at the same time have characteristics such as good stability and high activity, and can be used for the treatment and prevention of diseases related to the islet amyloid polypeptide receptor, such as abnormal body weight, particularly obesity and overweight.

The present disclosure relates to a novel isolated binding protein including a N-terminal pro-brain natriuretic peptide (NT-proBNP) antigen binding domain, and athe preparation method therefor. The antigen-binding domain includes at least one complementarity determining region selected from the amino acid sequences as defined in the present disclosure: or; has at least 80% sequence identity with the complementarity determining region of the following amino acid sequence and has an affinity of KD≤2.26×10-8 to NT-proBNP. The binding protein may be used in the detection field of NT-proBNP protein.

To provide hepcidin analogs with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.SOLUTION: The present invention relates generally to hepcidin analog peptides and methods of making and using the same. In certain embodiments, hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention is directed to hepcidin peptide analogs comprising one or more peptide subunits, wherein the peptide subunits form a cyclized structure via an intramolecular bond, e.g., an intramolecular disulfide bond. In certain embodiments, cyclized structures have increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life compared to hepcidin or conventional hepcidin analogs when delivered orally.SELECTED DRAWING: None